Dendreon ON Call provides
Immunity from Hassle
for practices using PROVENGE.
Dendreon ON Call is committed to helping you integrate PROVENGE into your practice
with comprehensive and convenient support throughout the PROVENGE process.
Select a topic to get started.
Comprehensive Support Throughout the PROVENGE Treatment Process
- Dendreon ON Call offers personalized PROVENGE support for your practice
- Dedicated case managers guide you through enrollment, rapid benefits verification, and patient assistance eligibility
- Dendreon ON Call scheduling coordinators arrange a patient’s full course of therapy and make reminder calls
- PROVENGE has robust coverage across commercial and government payers, and our reimbursement coordinators expertly provide coding, claims, and coverage support
- Dendreon ON Call offers a secure Provider Portal to track enrollment status and patient treatment progress
A Resource for Integrating PROVENGE
Dendreon ON Call provides convenient and comprehensive tools for practices. The PROVENGE Practice Pathway Resource Guide combines information and resources into one interactive reference tool to help integrate PROVENGE Immunotherapy into your practice.
Dendreon ON Call offers a secure and convenient Provider Portal for getting patients started with PROVENGE immunotherapy.
PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
IMPORTANT SAFETY INFORMATION
Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia. Closely monitor patients with cardiac or pulmonary conditions.
Thromboembolic events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.
Vascular disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.
Handling Precautions: PROVENGE is intended solely for autologous use and is not tested for transmissible infectious diseases.
Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.
Please see the Full Prescribing Information.